Collectively, these data showed that YAP1 inhibition impairs the initiation and maintenance of MLS tumors in vivo, further supporting the idea that overactive YAP1 signaling could represent a new target for therapeutic intervention in patients with FUS‐DDIT3‐driven MLS. Here, YAP1 is linked to McLeod neuroacanthocytosis syndrome.